NTHI
Neonc Technologies Holdings, Inc. NASDAQ$4.14
Mkt Cap $82.8M
52w Low $3.20
9.6% of range
52w High $12.99
50d MA $7.16
200d MA $8.21
P/E (TTM)
-1.3x
EV/EBITDA
-2.8x
P/B
—
Debt/Equity
-0.4x
ROE
355.0%
P/FCF
-7.6x
RSI (14)
—
ATR (14)
—
Beta
3.60
50d MA
$7.16
200d MA
$8.21
Avg Volume
51.5K
About
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcoho…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.37 | -0.46 | -25.4% | 7.01 | -0.1% | -13.1% | -15.1% | -18.1% | -17.0% | -23.4% | -36.9% | — |
| Nov 14, 2025 | AMC | -0.37 | -0.45 | -21.6% | 9.08 | +0.2% | -12.3% | -22.2% | -25.9% | -34.7% | -35.5% | +8.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | BTIG Research | Initiates | Buy | $15 | $4.79 | $5.30 | +10.6% | -0.2% | -3.8% | -10.0% | -10.2% | -7.7% |
Recent Filings
8-K · 1.01
!! High
NeOnc Technologies Holdings, Inc. -- 8-K 1.01: Material Agreement
NeOnc Technologies Holdings (NTHI) secured $10 million in funding through a Securities Purchase Agreement, providing capital for operations and growth initiatives.
Apr 24
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NeOnc disclosed material non-public information via Regulation FD, potentially signaling upcoming announcements about clinical progress or business developments that could significantly impact the biotech stock's valuation.
Apr 16
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
NTHI entered a material agreement with BTIG (a major investment bank), likely signaling capital raising, merger advisory, or strategic transaction discussions that could substantially alter the company's financial position or ownership structure.
Apr 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies disclosed material information via press release on April 1, 2026, which investors should review directly as it may impact stock valuation and trading decisions.
Apr 3
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
NTHI entered a material agreement that could significantly impact financial performance and investor returns, warranting immediate review of the full filing details to assess strategic implications.
Mar 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
NTHI's executive change involves new employment and equity compensation terms detailed in filed agreements, signaling potential leadership transition that could impact strategy and shareholder value depending on the executive's role and responsibilities.
Mar 17
8-K · 7.01
! Medium
NeOnc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies Holdings disclosed material information via press release on March 4, 2026, requiring investors to review Exhibit 99.1 for specific details about the company announcement.
Mar 6
8-K · 8.01
!! High
NeOnc Technologies Holdings, Inc. -- 8-K 8.01: Material Event / Announcement
NeOnc Technologies granted Fox Infused an intellectual property license and supply agreement for certain patented products, establishing a new revenue-generating partnership effective July 2022.
Mar 4
8-K · 1.01
!! High
NeOnc Technologies Holdings, Inc. -- 8-K 1.01: Material Agreement
NeOnc Technologies Holdings signed a $10 million securities purchase agreement, providing capital for operations and potential growth initiatives.
Mar 3
8-K · 7.01
! Medium
NeOnc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies will present early Phase 1 data from its NEO212-01 clinical trial on February 27, 2026, potentially demonstrating safety and dosing information for investors evaluating the company's development progress.
Feb 27
Data updated apr 26, 2026 3:57pm
· Source: massive.com